A pilot study of epidoxorubicin (NSC 256942) in combination treatment of acute leukaemia and non-Hodgkin's lymphoma.

Abstract

Epidoxorubicin (EDX) was administered to a group of 26 patients with acute leukaemia or lymphoma, replacing either daunorubicin or doxorubicin (DXR) as a component of multiple-chemotherapy regimens. In 10 patients with acute non-lymphocytic leukaemia treated at presentation, 5 complete and 4 partial remissions were obtained. All patients with lymphoma of… (More)

Topics

Cite this paper

@article{Eridani1984APS, title={A pilot study of epidoxorubicin (NSC 256942) in combination treatment of acute leukaemia and non-Hodgkin's lymphoma.}, author={Sandro Eridani and Thomas Pearson and Nicole Slater and A. K. Singh}, journal={Oncology}, year={1984}, volume={41 6}, pages={383-6} }